Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385944
Status:
COMPLETED
Last Update Posted:
2010-09-16
First Post:
2006-10-06
Brief Title:
The Effect on Blood Cells Known as Platelets Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome ACS
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Double-Blind Cross-Over Study Comparing the Pharmacodynamic PDResponse in Subjects With ACS Receiving 14 Days 10-mg Maintenance Dose MD Prasugrel vs 14 Days 150-mg MD Clopidogrel After Using a 900-mg Loading Dose LD of Clopidogrel to Reduce Ongoing Platelet Activation
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter randomized double-blind cross-over study to compare the pharmacodynamic response in subjects with Acute Coronary Syndrome receiving a 10-mg maintenance dose MD of prasugrel compared with a 150-mg maintenance dose of clopidogrel following a 900-mg loading dose LD of clopidogrel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H7T-MC-TABN | OTHER | Eli Lilly and Company | None |